Thursday, May 11, 2017

BRIEF-Corbus announces last subject enrolled in Phase 2 study of anabasum

* Corbus pharmaceuticals announces last subject enrolled in phase 2 study of anabasum for the treatment of skin-predominant dermatomyositis

by reutersCOMPANYNEWS via Endless Supplies .Biz - News
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)